• Bergenin Targets γδT17 Cells in Psoriasis via PPARγ-PROX1 Ax

  2026-06-05

  This study uncovers how bergenin, a natural PPARγ agonist from Bergenia purpurascens, selectively suppresses pathogenic γδT17 cells to ameliorate psoriasis. By elucidating a PPARγ-mediated mechanism that degrades PROX1 and inhibits IL-17A production, the findings advance our understanding of metabolic and transcriptional control in psoriatic inflammation.

• Zoledronic Acid: Optimizing Cancer Cell Apoptosis & Bone Dis

  2026-06-05

  Zoledronic Acid, a nitrogen-containing bisphosphonate, empowers research on cancer cell apoptosis and bone disease prevention through rigorously validated protocols. Explore advanced use-cases, stepwise workflows, and actionable troubleshooting tips to maximize experimental reliability and translational insight.

• Zosuquidar (LY335979) for Multidrug Resistance Reversal in C

  2026-06-04

  Zosuquidar (LY335979) 3HCl enables researchers to directly reverse P-glycoprotein-mediated multidrug resistance (MDR), restoring chemotherapeutic efficacy in resistant cancer models. This guide translates cutting-edge mechanistic insights and experimental protocols into actionable workflows, with troubleshooting tips to maximize impact in both preclinical and translational oncology research.

• Ampicillin Sodium: Mechanistic Insight and Translational Lev

  2026-06-04

  This thought-leadership article explores how Ampicillin sodium, a β-lactam antibiotic, underpins translational advances in antibacterial research. We blend mechanistic rationale, experimental best practices, and competitive benchmarking—anchored by new comparative data and actionable guidance for researchers seeking to optimize efficacy in both in vitro and in vivo antibacterial studies.

• L-Glutathione Reduced: Optimizing Redox and GST Workflows

  2026-06-03

  L-Glutathione Reduced enables high-fidelity redox and GST affinity workflows, delivering reproducible results in oxidative stress and cancer metabolism research. This guide translates the latest mechanistic insights into actionable protocols and troubleshooting strategies, leveraging APExBIO’s trusted reagent for robust, publication-grade data.

• Pazopanib Hydrochloride: Next-Gen Oncology Workflows & Proto

  2026-06-03

  Pazopanib Hydrochloride (GW786034) empowers cancer researchers with multi-target kinase inhibition and reproducible anti-angiogenic effects. This article translates the latest in vitro evaluation strategies and troubleshooting insights into actionable protocols, informed by benchmarked evidence and comparative analyses.

• Staurosporine: Elevating Translational Oncology with Mechani

  2026-06-02

  Staurosporine, a benchmark broad-spectrum serine/threonine protein kinase inhibitor, is reshaping translational cancer research by enabling precise dissection of kinase signaling, apoptosis, and angiogenesis inhibition. This thought-leadership article blends mechanistic understanding with actionable protocol guidance, spotlights APExBIO’s gold-standard Staurosporine, and bridges advanced methodologies such as high-throughput fractional killing quantification. We contextualize new evidence about therapy-induced prometastatic states and provide a strategic roadmap for researchers seeking to translate molecular findings into innovative anti-cancer strategies.

• Cinoxacin in Gram-Negative Infection Models: Protocols & Ins

  2026-06-02

  Cinoxacin, a classic quinolone antibiotic, empowers researchers with precise inhibition of Gram-negative bacteria, making it indispensable for urinary tract infection research and resistance profiling. This guide translates evidence-backed protocols and troubleshooting strategies into actionable workflows, leveraging APExBIO's Cinoxacin for reproducibility and data-driven results.

• LY364947: Reliable TGF-β Type I Receptor Kinase Inhibitor fo

  2026-06-01

  This article examines real laboratory challenges in TGF-β/EMT research and demonstrates how LY364947 (SKU B2287) serves as a reproducible, high-quality solution for cell viability, proliferation, and cytotoxicity studies. Through data-supported scenario analyses, we highlight protocol optimization, assay compatibility, and vendor reliability, establishing LY364947 as a trusted tool for robust experimental outcomes.

• Sodium Picosulfate: Applied Workflows in Gut–Liver–Brain Res

  2026-06-01

  Sodium Picosulfate, supplied by APExBIO, accelerates translational research in gastrointestinal and neuroinflammation models by enabling precise modulation of water and electrolyte dynamics. This article translates cutting-edge evidence into actionable protocols and troubleshooting tactics for chronic constipation and gut–liver–brain axis studies.

• Gut Microbiota Modulates PCN’s Hepatoprotection via YAP in S

  2026-05-31

  This study demonstrates that gut microbiota is essential for the protective effects of the mouse PXR agonist Pregnenolone-16α-carbonitrile (PCN) against sepsis-induced liver injury, acting through YAP pathway activation. The findings highlight a novel gut-liver axis mechanism, informing future research on hepatic detoxification and antifibrotic strategies.

• Cand2 Modulates Ubiquitination and Autophagy in Fungal Patho

  2026-05-30

  This study identifies Cand2 as a key inhibitor of CRL-mediated ubiquitination, regulating autophagy and pathogenicity in the rice blast fungus Magnaporthe oryzae. The work reveals conserved mechanisms linking protein homeostasis to fungal virulence, offering new targets for crop protection strategies.

• CBD Reduces Orofacial Inflammatory Pain via Endocannabinoid

  2026-05-29

  This study demonstrates that cannabidiol (CBD) robustly attenuates both sensory and affective dimensions of orofacial inflammatory pain in mice. By dissecting peripheral and central endocannabinoid signaling, the research provides a translational foundation for novel therapies targeting complex pain syndromes and their emotional comorbidities.

• Balsalazide as a Targeted 5-ASA Prodrug for Ulcerative Colit

  2026-05-29

  The reference study by Wiggins & Rajapakse introduces balsalazide as a novel prodrug formulation for delivering 5-aminosalicylate in the treatment of active ulcerative colitis. The review highlights the drug’s improved efficacy in remission induction and rapidity of onset, alongside a favorable safety profile, compared to other oral 5-ASA agents. These findings have important implications for optimizing anti-inflammatory strategies in gastrointestinal research.

• Phosphatase Inhibitor Cocktail 1: Optimizing Phosphoproteomi

  2026-05-28

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO empowers researchers to preserve phosphorylation states with precision across demanding proteomic and signaling assays. By targeting both alkaline and serine/threonine phosphatases, this cocktail ensures data integrity for Western blotting, co-immunoprecipitation, and advanced phosphoproteomic analysis.

16400 records 1/1094 page Next 12345 下5页 Last page